| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Trade names | Kostaive |
| Other names | ARCT-154, MRNA-2105 |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Zapomeran, sold under the brand name Kostaive is a self-amplifying mRNA-based COVID-19 vaccine. [1] It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. [1] Self-amplifying means that the mRNA also carries instructions to make a protein called replicase. [1]
Zapomeran was approved for medical use in Japan in November 2023, and it is the first self-amplifying mRNA-based COVID-19 vaccine to be approved. [3] [4] Zapomeran was authorized for medical use in the European Union in February 2025. [1] [2]
Zapomeran is used to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus. [1]
Kostaive was approved for medical use in Japan in November 2023. [5] [6] [7]
In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kostaive, a vaccine intended for the prevention of COVID-19 in adults. [1] The applicant for this medicinal product is Arcturus Therapeutics Europe B.V. [1] Zapomeran was authorized for medical use in the European Union in February 2025. [1] [2]
Zapomeran is the international nonproprietary name. [8] [9]
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
